Table 1.

Clinical and epidemiological characteristics.

Demographic variables	All	Train	Test	p-value
Patients (n)	61	42	19
Sex, male (%)	49 (80.3)	35 (83.3)	14 (73.7)	0.380
Median age at diagnosis (years)	66 (37–86)	67 (37–86)	63 (50–86)	0.323
Median time diagnosis to TACE (days)	43 (3–978)	42 (3–874)	59 (17–978)	0.252
Median size of Target lesions (cm)	2.9 (1.0–10.1)	2.2 (1.0–9.8)	3.4 (1.0–10.1)	0.143
Cause of HCC (%)				0.968
Hepatitis B	9 (14.8)	6 (14.3)	3 (15.8)
Hepatitis C	14 (23.0)	10 (23.8)	4 (21.1)
Alcohol	19 (31.1)	14 (33.3)	5 (26.3)
NASH	5 (8.2)	3 (7.1)	2 (10.5)
Alcohol + viral Hepatitis	6 (9.8)	4 (9.5)	2 (10.5)
Alcohol + NASH	1 (1.6)	1 (2.4)	0 (0)
Others (cryptogenic cirrhosis, AIH)	7 (11.5)	4 (9.5)	3 (15.8)
BCLC prior to TACE				0.092
A	18 (29.5)	14 (33.3)	4 (21.1)
B	33 (54.1)	24 (57.1)	9 (47.4)
C	10 (16.4)	4 (9.5)	6 (31.6)
D	0 (0.0)	0 (0.0)	0 (0.0)
Child Pugh Score prior to TACE				0.644
A	36 (59.0)	25 (59.5)	11 (57.9)
B	6 (9.8)	5 (11.9)	1 (5.3)
C	0 (0.0)	0 (0.0)	0 (0.0)
N/A	19 (31.1)	12 (28.6)	7 (36.8)
MELD-Score prior to TACE				0.141
< 6	1 (1.6)	0 (0.0)	1 (5.3)
< 10	23 (37.7)	13 (31.0)	10 (52.6)
< 15	11 (18.0)	10 (23.8)	1 (5.3)
< 20	1 (1.6)	1 (2.4)	0 (0.0)
N/A	25 (41.0)	18 (42.9)	7 (36.8)
Median albumin (g/dl)	3.8 (1.8–7.2)	3.8 (1.8–7.2)	3.9 (3.0–4.5)	0.686
Median bilirubin (mg/dl)	0.8 (0.3–2.2)	1.1 (0.3–2.2)	0.9 (0.3–1.3)	0.540
Median INR	1.1 (0.9–3.3)	1.1 (0.9–3.3)	1.1 (1.0–1.8)	0.204
Median CRP (mg/dl)	0.4 (0.03–4.4)	0.5(0.03- 4.4)	0.3 (0.1–2.9)	0.632
Median AFP (ng/ml)	12.9 (2.1–60,500.0)	9.2 (2.1–60,500.0)	17.3 (2.2–9276.0)	0.615

The train and test set were statistically analyzed using the Pearson Chi-Square test or two-sided t-test for ordinal or continuous outcomes.